Nkarta Inc (NAS:NKTX)
$ 3.03 0.16 (5.57%) Market Cap: 213.82 Mil Enterprise Value: 4.93 Mil PE Ratio: 0 PB Ratio: 0.50 GF Score: 38/100

Nkarta Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 12, 2022 / 08:30PM GMT
Release Date Price: $9.04 (-10.85%)
Chang Liu
Needham & Company - Analyst

Good afternoon and welcome to the 21st Needham healthcare conference. My name is Chang Liu and I will be the moderator for this presentation. We welcome Nkarta here today and its CFO, Nadir Mahmood. (Operator Instructions)

Without further ado, Nadir, would you like to start your presentation?

Nadir Mahmood
Nkarta, Inc. - Chief Financial and Business Officer

Great. Thank you, Chang, and thank you to yourself and Gil and the team at Needham for the invitation and the opportunity to speak today. Really looking forward to this. So I'm going to be talking today about Nkarta Therapeutics. We are a natural killer cell company designing engineered CAR-NK cells in oncology. As a reminder, I will be making forward-looking statements during the course of my presentation today.

So at Nkarta, we fundamentally believe that what we've built is the next revolution in cell therapy. We have spent the last several years developing and designing a natural killer cell platform to tackle blood cancers and solid tumors

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot